Research map: Population pharmacokinetic modeling of amisulpride drug interactions and a transporter binding analysis

Back to the article

Papers in this map

  1. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 · * · 2022 · 6559 citations · Cited by this paper
  2. The Effect of the combination therapy of statin and dapagliflozin, a selective inhibitor of sodium_glucose Co-transporter type 2, in the treatment of Ischemic heart disease with heart failure: A randomized controlled trial · 2026 · Related
  3. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis · Maximilian Huhn · 2019 · 1795 citations · Cited by this paper
  4. Acetaminophen exposure in an aging population and neurodegenerative outcomes · 2026 · Related
  5. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis · Toby Pillinger · 2019 · 1082 citations · Cited by this paper
  6. Population pharmacokinetics of unbound imipenem in critically ill patients: a comparison of five renal function estimators for PK/PD-guided dosing · 2026 · Related
  7. Sex differences in pharmacokinetics predict adverse drug reactions in women · Irving Zucker · 2020 · 813 citations · Cited by this paper
  8. Faster dementia progression was associated with use of potentially inappropriate medications · 2026 · Related
  9. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment · Robert Ali McCutcheon · 2023 · 765 citations · Cited by this paper
  10. Examining the risk of neurotoxicity in patients who receive unadjusted doses of oral beta-lactams in renal insufficiency: a retrospective cohort study · 2026 · Related
  11. Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019 · Marco Solmi · 2023 · 583 citations · Cited by this paper
  12. Secondary data analysis of Adverse Drug Reactions reported by healthcare professionals and patients: interventions to manage ADRs of ACE inhibitors and ARBs · 2026 · Related
  13. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia · Stefan Leucht · 2019 · 303 citations · Cited by this paper
  14. Detection of intravenous drug physicochemical incompatibilities in clinical practice: e-Harvis compared to reference tools · 2026 · Related
  15. Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences · Marco Carli · 2021 · 253 citations · Cited by this paper
  16. Effects of renal impairment on the pharmacokinetics, safety, and tolerability of pudexacianinium (ASP5354) after IV administration: a mechanistic exploration · 2026 · Related
  17. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers · Pierre Rosenzweig · 2002 · 183 citations · Cited by this paper
  18. Authors response to the comments by Muhammad Salman, Muhammad Hammad Chola and Muhammad Hasan on our paper “prescribing patterns of glucagon like peptide-1 receptor agonists in the Swedish capital region: a register-based cross-sectional study” · 2026 · Related
  19. Prevalence of Overweight and Obesity in People With Severe Mental Illness: Systematic Review and Meta-Analysis · Medhia Afzal · 2021 · 167 citations · Cited by this paper
  20. Response to comment on “CYP2C19 genotyping and mavacamten: predicting outcomes in normal, intermediate and rapid metabolisers in obstructive hypertrophic cardiomyopathy” · 2026 · Related
  21. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds — implications for pharmacokinetics of selected substrates · Amal Abou el ela · 2004 · 143 citations · Cited by this paper
  22. Habitual daily intake of a sweet and fatty snack modulates reward processing in humans · Sharmili Edwin Thanarajah · 2023 · 134 citations · Cited by this paper
  23. Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials · Hui Wu · 2022 · 130 citations · Cited by this paper
  24. The Poorly Membrane Permeable Antipsychotic Drugs Amisulpride and Sulpiride Are Substrates of the Organic Cation Transporters from the SLC22 Family · Joao N.S. Pereira · 2014 · 104 citations · Cited by this paper
  25. Amisulpride – dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring · Anna Sparshatt · 2009 · 88 citations · Cited by this paper
  26. Amisulpride · Monique P Curran · 2001 · 80 citations · Cited by this paper
  27. Does Switching Antipsychotics Ameliorate Weight Gain in Patients With Severe Mental Illness? A Systematic Review and Meta-analysis · Dan J. Siskind · 2020 · 75 citations · Cited by this paper
  28. Epigenetics of Schizophrenia · Anil Srivastava · 2021 · 70 citations · Cited by this paper
  29. Molecular basis of polyspecific drug and xenobiotic recognition by OCT1 and OCT2 · Yang Suo · 2023 · 69 citations · Cited by this paper
  30. A Compilation of Serum Concentrations of 12 Antipsychotic Drugs in a Therapeutic Drug Monitoring Setting · Anna Kristina Jönsson · 2018 · 63 citations · Cited by this paper
  31. Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp) · Ulrich Schmitt · 2005 · 58 citations · Cited by this paper
  32. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with Schizophrenia · Matthias J. Müller · 2005 · 57 citations · Cited by this paper
  33. Region-specific blood–brain barrier transporter changes leads to increased sensitivity to amisulpride in Alzheimer’s disease · Gayathri Nair Sekhar · 2019 · 56 citations · Cited by this paper
  34. Adjunctive metformin for antipsychotic-induced hyperprolactinemia: A systematic review · Qijing Bo · 2016 · 52 citations · Cited by this paper
  35. Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: A meta-analysis · Maarten Bak · 2021 · 50 citations · Cited by this paper
  36. Significant impact of time-of-day variation on metformin pharmacokinetics · Denise Türk · 2023 · 34 citations · Cited by this paper
  37. In vitro P-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes · Ulrich Schmitt · 2012 · 30 citations · Cited by this paper
  38. Development of a UPLC‐MS/MS method for routine therapeutic drug monitoring of aripiprazole, amisulpride, olanzapine, paliperidone and ziprasidone with a discussion of their therapeutic reference ranges for Chinese patients · Shao‐Ting Wang · 2017 · 29 citations · Cited by this paper
  39. A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer’s disease · Suzanne Reeves · 2016 · 24 citations · Cited by this paper

Source: OpenAlex (CC0)